Allergan plc Company Profile (NYSE:AGN)

About Allergan plc (AGN)

Allergan plc logoAllergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: AGN
  • CUSIP: 01849010
Key Metrics:
  • Previous Close: $243.05
  • 50 Day Moving Average: $238.44
  • 200 Day Moving Average: $221.70
  • 52-Week Range: $184.50 - $261.27
  • Trailing P/E Ratio: 6.39
  • Foreward P/E Ratio: 13.57
  • P/E Growth: 1.09
  • Market Cap: $81.75B
  • Outstanding Shares: 335,224,000
  • Beta: 1.07
  • Net Margins: 100.04%
  • Return on Equity: 7.21%
  • Return on Assets: 4.00%
  • Debt-to-Equity Ratio: 0.37%
  • Current Ratio: 3.95%
  • Quick Ratio: 3.86%

Analyst Ratings

Consensus Ratings for Allergan plc (NYSE:AGN) (?)
Ratings Breakdown: 4 Hold Ratings, 14 Buy Ratings
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $266.29 (9.20% upside)

Analysts' Ratings History for Allergan plc (NYSE:AGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/24/2017Citigroup IncBoost Price TargetBuy$261.00LowView Rating Details
4/12/2017Royal Bank of CanadaSet Price TargetBuy$279.00LowView Rating Details
3/28/2017Deutsche Bank AGBoost Price TargetBuy$262.00 -> $265.00LowView Rating Details
2/22/2017Piper Jaffray CompaniesSet Price TargetHold$205.00N/AView Rating Details
2/14/2017Credit Suisse Group AGReiterated RatingBuy$274.00N/AView Rating Details
2/9/2017Leerink SwannBoost Price TargetBuy$280.00N/AView Rating Details
2/7/2017MizuhoReiterated RatingBuy$273.00 -> $275.00N/AView Rating Details
1/18/2017Goldman Sachs Group IncReiterated RatingPositive -> Buy$240.00 -> $250.00N/AView Rating Details
12/25/2016Sanford C. BernsteinSet Price TargetBuy$275.00N/AView Rating Details
12/23/2016Bank of America CorpReiterated RatingBuy$280.00N/AView Rating Details
12/6/2016ArgusReiterated RatingBuy$340.00 -> $260.00N/AView Rating Details
12/5/2016JPMorgan Chase & Co.Set Price TargetBuy$300.00N/AView Rating Details
11/21/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
11/3/2016Morgan StanleyLower Price TargetOverweight$300.00 -> $274.00N/AView Rating Details
10/31/2016Barclays PLCReiterated RatingEqual Weight$250.00N/AView Rating Details
9/21/2016Cantor FitzgeraldDowngradeBuy -> HoldN/AView Rating Details
6/10/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
5/24/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
4/18/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
4/7/2016Raymond James Financial, Inc.Lower Price TargetOutperform$317.00 -> $275.00N/AView Rating Details
4/7/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
4/7/2016Susquehanna Bancshares IncDowngradePositive -> Neutral$345.00 -> $275.00N/AView Rating Details
4/5/2016NomuraReiterated RatingBuy$350.00 -> $330.00N/AView Rating Details
6/20/2015BMO Capital MarketsSet Price TargetBuy$378.00N/AView Rating Details
(Data available from 4/29/2015 forward)


Earnings History for Allergan plc (NYSE:AGN)
Earnings by Quarter for Allergan plc (NYSE:AGN)
Earnings History by Quarter for Allergan plc (NYSE:AGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/8/2017Q416$3.76$3.90$3.77 billion$3.86 billionViewListenView Earnings Details
11/2/2016Q316$3.57$3.32$3.73 billion$3.62 billionViewListenView Earnings Details
8/8/2016Q216$3.34$3.35$4.10 billion$3.68 billionViewListenView Earnings Details
5/10/2016Q116$3.03$3.04$3.97 billion$3.80 billionViewListenView Earnings Details
2/22/2016Q415$3.36$3.41$4.20 billion$4.20 billionViewListenView Earnings Details
11/4/2015Q315$3.20$3.48$5.71 billion$4.10 billionViewN/AView Earnings Details
8/6/2015Q215$4.41$4.41$5.71 billion$5.76 billionViewN/AView Earnings Details
11/5/2014Q414$1.83$2.17$1.90 billion$1.91 billionViewN/AView Earnings Details
8/5/2014Q314$1.76$1.78$1.78 billion$1.79 billionViewListenView Earnings Details
7/21/2014Q214$1.44$1.51$1.77 billion$1.83 billionViewN/AView Earnings Details
4/30/2014Q114$1.13$1.18$1.60 billion$1.65 billionViewN/AView Earnings Details
2/4/2014Q413$1.34$1.12$1.65 million$1.66 millionViewN/AView Earnings Details
10/29/2013Q313$1.20$1.23$1.53 billion$1.23 billionViewListenView Earnings Details
7/31/2013Q2 2013$1.20$1.22$1.56 billion$1.60 billionViewN/AView Earnings Details
5/1/2013Q1 2013$0.96$0.98$1.44 billion$1.46 billionViewN/AView Earnings Details
2/5/2013Q4 2012$1.20$1.15$1.51 million$1.48 millionViewN/AView Earnings Details
10/30/2012Q312$1.04$1.06$1.43 billion$1.39 billionViewN/AView Earnings Details
8/1/2012$1.06$1.07ViewN/AView Earnings Details
5/2/2012$0.87$0.86ViewN/AView Earnings Details
2/2/2012$1.00$1.00ViewN/AView Earnings Details
10/26/2011$0.90$0.92ViewN/AView Earnings Details
8/3/2011$0.95$0.96ViewN/AView Earnings Details
5/4/2011$0.74$0.77ViewN/AView Earnings Details
2/2/2011$0.89$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Allergan plc (NYSE:AGN)
2017 EPS Consensus Estimate: $16.04
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$3.33$3.55$3.44
Q2 20172$3.85$4.07$3.96
Q3 20172$4.09$4.16$4.13
Q4 20172$4.35$4.67$4.51
(Data provided by Zacks Investment Research)


Current Dividend Information for Allergan plc (NYSE:AGN)
Most Recent Dividend:3/28/2017
Annual Dividend:$2.80
Dividend Yield:1.15%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:7.48% (Trailing 12 Months of Earnings)
17.47% (Based on This Year's Estimates)
15.58% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Allergan plc (NYSE:AGN)

Dividend History by Quarter for Allergan plc (NYSE:AGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Allergan plc (NYSE:AGN)
Insider Ownership Percentage: 0.27%
Institutional Ownership Percentage: 86.40%
Insider Trades by Quarter for Allergan plc (NYSE:AGN)
Institutional Ownership by Quarter for Allergan plc (NYSE:AGN)
Insider Trades by Quarter for Allergan plc (NYSE:AGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/2/2017Paul BisaroDirectorSell70,000$246.68$17,267,600.00View SEC Filing  
12/8/2016Nesli BasgozDirectorSell500$188.72$94,360.00View SEC Filing  
11/21/2016Brent L. SaundersCEOBuy5,250$189.13$992,932.50View SEC Filing  
11/11/2016Maria Teresa HiladoCFOBuy1,422$210.64$299,530.08View SEC Filing  
6/2/2016Maria Teresa HiladoCFOBuy661$241.57$159,677.77View SEC Filing  
5/11/2016Nesli BasgozDirectorSell459$225.10$103,320.90View SEC Filing  
12/7/2015Nesli BasgozDirectorSell2,300$312.96$719,808.00View SEC Filing  
8/24/2015Paul BisaroChairmanBuy1,000$297.42$297,420.00View SEC Filing  
8/21/2015Brent L SaundersCEOBuy1,000$301.94$301,940.00View SEC Filing  
4/22/2014Scott ShermanEVPSell14,500$155.82$2,259,390.00View SEC Filing  
2/21/2014Louis Lavigne, Jr.DirectorSell5,400$125.79$679,266.00View SEC Filing  
2/19/2014Dawn HudsonDirectorSell4,200$126.35$530,670.00View SEC Filing  
2/19/2014Jeffrey EdwardsCFOSell38,900$126.39$4,916,571.00View SEC Filing  
2/19/2014Raymond DiradoorianEVPSell23,000$126.66$2,913,180.00View SEC Filing  
2/18/2014Scott ShermanEVPSell5,001$125.74$628,825.74View SEC Filing  
1/14/2014Scott WhitcupVPSell42,000$117.80$4,947,600.00View SEC Filing  
12/27/2013Julian GangolliVPSell52,500$110.05$5,777,625.00View SEC Filing  
12/20/2013Scott WhitcupVPSell33,000$108.80$3,590,400.00View SEC Filing  
10/15/2013Trevor JonesDirectorSell2,000$90.14$180,280.00View SEC Filing  
9/16/2013Trevor JonesDirectorSell2,000$89.78$179,560.00View SEC Filing  
8/15/2013Trevor JonesDirectorSell2,000$89.89$179,780.00View SEC Filing  
8/6/2013Jeffrey EdwardsCFOSell69,200$91.17$6,308,964.00View SEC Filing  
7/15/2013Trevor M JonesDirectorSell2,000$91.15$182,300.00View SEC Filing  
6/17/2013Trevor M JonesDirectorSell2,000$101.25$202,500.00View SEC Filing  
5/15/2013Trevor M JonesDirectorSell2,000$103.40$206,800.00View SEC Filing  
5/9/2013Jeffrey L EdwardsCFOSell84,000$103.49$8,693,160.00View SEC Filing  
11/26/2012Trevor M JonesDirectorSell2,500$91.30$228,250.00View SEC Filing  
10/5/2012David E I PyottCEOSell616,300$93.73$57,765,799.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Allergan plc (NYSE:AGN)
Latest Headlines for Allergan plc (NYSE:AGN)
DateHeadline logoSomewhat Positive News Coverage Very Likely to Affect Allergan plc (AGN) Share Price - April 29 at 10:22 AM logo$3.32 Earnings Per Share Expected for Allergan plc (AGN) This Quarter - April 27 at 9:54 AM logoAllergan (AGN) Granted Marketing Authorization by the FDA for TrueTear - April 26 at 8:38 PM logoSomewhat Favorable Press Coverage Very Likely to Affect Allergan plc (AGN) Share Price - April 26 at 2:12 PM logoAllergan (AGN) Granted Marketing Authorization by the FDA for TrueTear - - April 26 at 7:09 AM logoAt high-stakes table, growing Peninsula biotech antes up with 'fatty-liver' drug - April 25 at 3:24 PM logoAllergan Announces Marketing Authorization For TrueTear - Quick Facts - April 25 at 3:24 PM logoGilead Sciences: NASH Bridges…To What? - April 25 at 3:24 PM logoAllergan Granted Marketing Authorization by the FDA for TrueTear™, the First Intranasal Neurostimulating … - April 25 at 8:02 AM logoAllergan Granted Marketing Authorization by the FDA for TrueTear™, the First Intranasal Neurostimulating Device Proven to Temporarily Increase Tear Production - April 25 at 8:02 AM logoAllergan plc (AGN) Given New $261.00 Price Target at Citigroup Inc - April 24 at 7:50 PM logoNovartis’s 1Q17 Estimates for Sandoz - April 24 at 10:57 AM logo3 Healthcare Bargain Stocks You Can Buy Right Now - April 24 at 10:57 AM logoDr. Steven James Joins Insys Therapeutics as Vice President of Medical Affairs - April 24 at 7:19 AM logoSomewhat Positive Press Coverage Very Likely to Impact Allergan plc (AGN) Stock Price - April 23 at 7:48 AM logoAllergan plc (AGN) Given "Focus List" Rating at Citigroup Inc - April 21 at 10:51 AM logoAllergan (AGN) Collaborates with Novartis to Treat NASH - Nasdaq - April 20 at 3:27 PM logoSomewhat Favorable Media Coverage Very Likely to Impact Allergan plc (AGN) Share Price - April 20 at 10:47 AM logoAllergan, Argentum settle patent dispute over eye drug Restasis - April 19 at 6:28 AM logoAllergan and Novartis team up in NASH study - Seeking Alpha - April 18 at 3:22 PM logoAllergan: The Triumph Of Financial Engineering Over Reality - Seeking Alpha - April 18 at 3:22 PM logoAllergan, Novartis In Clinical Trial Deal To Treat NASH - April 18 at 7:04 AM logoAllergan, Novartis In Clinical Trial Deal To Treat NASH - Quick Facts - April 18 at 7:04 AM logoAllergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration - April 18 at 7:04 AM logoAllergan plc (AGN) Earns News Impact Score of 0.21 - April 17 at 11:37 AM logoAllergan plc (AGN) Short Interest Up 32.5% in March - April 16 at 8:00 AM logoChartMasterPro: Quarterly Review Of Our Stock Picks - April 16 at 6:33 AM logoAllergan plc (AGN) Given Daily Coverage Optimism Score of 0.09 - April 14 at 3:50 PM logoAllergan plc (AGN) Given a $279.00 Price Target by Royal Bank of Canada Analysts - April 13 at 6:14 PM logoVOO, BMY, GILD, AGN: Large Inflows Detected at ETF - April 12 at 3:23 PM logoAllergan Launches Frames of Mind, Encouraging People Living with Migraine to Share Common Experiences Through Art - April 11 at 8:18 AM logoAllergan plc Sees Unusually High Options Volume (AGN) - April 10 at 2:26 PM logoValeant: It's Not a Game of Chess - Part IV - April 10 at 6:14 AM logoTakeaways and Observations; Play a Tesla Tune: Doug Kass' Views - April 10 at 6:14 AM logoAllergan plc (AGN) Lifted to "Buy" at Vetr Inc. - April 9 at 6:56 PM logoWhy Is Allergan (AGN) Down 2.2% Since the Last Earnings Report? - April 8 at 3:21 PM logoAllergan plc (AGN) Expected to Announce Quarterly Sales of $3.54 Billion - April 7 at 9:01 PM logoAllergan is still hopeful about using Botox to treat depression - April 7 at 4:19 PM logoAllergan Teams Up With Media Mogul Wendy Williams to Debut the Patient Empowerment Campaign - Toilet Talk - April 7 at 3:25 PM logoAllergan plc (AGN) Expected to Announce Earnings of $3.36 Per Share - April 5 at 6:28 PM logoAllergan plc (AGN) Given Consensus Rating of "Buy" by Analysts - April 4 at 10:28 PM logoHere's the Bill Ackman apology Wall Street's been waiting for - March 29 at 8:32 PM logoBill Ackman's Insider Trading Lawsuit May Cost Pershing Square Investors $75 Million - March 29 at 8:06 PM logoAllergan: Where Is The Buyback Signal Now? - Seeking Alpha - March 28 at 3:22 PM logoAllergan - Seeking Alpha - March 28 at 3:22 PM logoAllergan Acne Candidate Meets Endpoints in Phase III Studies - March 28 at 3:22 PM logoDeutsche Bank AG Increases Allergan plc (AGN) Price Target to $265.00 - March 28 at 10:19 AM logoHealth care showdown: Allergan vs. Valeant - March 28 at 8:36 AM logoWhy Impax Labs Soared 37.3% Today - March 28 at 8:36 AM logoAllergan, Paratek Report Positive Results From Two Phase 3 Trials Of Sarecycline - March 27 at 3:31 PM


Frequently Asked Questions for Allergan plc (NYSE:AGN)

What is Allergan plc's stock symbol?

Allergan plc trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan plc pay dividends? What is the dividend yield for Allergan plc?

Allergan plc declared a quarterly dividend on Wednesday, November 2nd. Stockholders of record on Tuesday, February 28th will be paid a dividend of $0.70 per share on Tuesday, March 28th. This represents a $2.80 annualized dividend and a dividend yield of 1.15%. The ex-dividend date of this dividend is Friday, February 24th. This is an increase from Allergan plc's previous quarterly dividend of $0.05.

How were Allergan plc's earnings last quarter?

Allergan plc (NYSE:AGN) issued its earnings results on Wednesday, February, 8th. The company reported $3.90 earnings per share for the quarter, topping the consensus estimate of $3.76 by $0.14. The company earned $3.86 billion during the quarter, compared to analyst estimates of $3.77 billion. Allergan plc had a return on equity of 7.21% and a net margin of 100.04%. The company's revenue for the quarter was up 7.1% on a year-over-year basis. During the same period last year, the company posted $3.41 EPS.

When will Allergan plc make its next earnings announcement?

Allergan plc is scheduled to release their next quarterly earnings announcement on Monday, May, 8th 2017.

What guidance has Allergan plc issued on next quarter's earnings?

Allergan plc issued an update on its FY17 earnings guidance on Wednesday, February, 8th. The company provided earnings per share (EPS) guidance of $15.80-16.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.99. The company issued revenue guidance of $15.5-15.8 billion, compared to the consensus revenue estimate of $15.26 billion.

Where is Allergan plc's stock going? Where will Allergan plc's stock price be in 2017?

18 equities research analysts have issued 12-month target prices for Allergan plc's shares. Their predictions range from $205.00 to $300.00. On average, they expect Allergan plc's share price to reach $266.29 in the next year.

What are analysts saying about Allergan plc stock?

Here are some recent quotes from research analysts about Allergan plc stock:

  • 1. Leerink Swann analysts commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic franchises we're modestly raising our sales and EPS estimates." (2/9/2017)
  • 2. According to Zacks Investment Research, "Allergan is reshaping its portfolio through acquisitions/divestitures. Allergan has been pretty active on the acquisition front and made six new product acquisitions in the third quarter. With the Allergan, Inc. acquisition, the company finds itself among the top 10 pharmas worldwide based on sales. Moreover, with the closing of the Teva deal, the company’s restructured and simplified business is encouraging. As a result, Allergan can now focus on the branded segment and is using the proceeds to buy back shares, pay down debt and pursue additional deals. Biosimilars also represent significant opportunity. Also, Allergan’s shares outperformed the generic industry in past six months. However, while we remain optimistic about the company’s growth prospects, the company is facing generic threat for Namenda IR as well as patent challenges for some of the other products in its branded portfolio, which concerns us." (1/3/2017)
  • 3. Citigroup Inc analysts commented, "should not be overlooked."Allergan's first-quarter adjusted earnings of $3.04 per share topped the Street's estimate of $3.01. The company's adjusted top line grew 48.1 percent to $3.9 billion, yet came in below consensus view of $3.95 billion. Related Link: Allergan Q1 Adjusted Earnings Beat Predictions"While AGN's 1Q16 revenues missed consensus expectations, we note the strong performance of key brands (Botox, Linzess, Lumigan, Alphagan, dermal fillers) vs. Street expectations," analyst Liav Abraham wrote in a note.Share Buyback ProgramThe Botox maker also authorized a new $10 billion share buyback program, of which $4 billion–$5 billion is expected to be executed over the next four to six months."While the share buyback signals management's view regarding the stock's valuation, it also preserves meaningful optionality for execution on incremental business development opportunities," Abraham noted.A Look ForwardLooking ahead, Allegan still sees adjusted revenues of $17 billion for the current year. That included branded net revenue of $15 billion. The Street analysts expect the company to deliver $16.88 billion revenue. The company indicated that its non-GAAP R&D is expected to be $1.5 billion."While the positive development of a share buyback may be moderated by the 1Q16 top-line miss, we maintain our view regarding the quality of AGN's core assets and the company's growth profile vs. the peer group," (5/11/2016)

Are investors shorting Allergan plc?

Allergan plc saw a increase in short interest in the month of March. As of March 31st, there was short interest totalling 11,289,935 shares, an increase of 32.5% from the March 15th total of 8,520,757 shares. Based on an average daily volume of 2,725,545 shares, the short-interest ratio is presently 4.1 days. Currently, 3.4% of the shares of the company are short sold.

Who owns Allergan plc stock?

Allergan plc's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Strs Ohio (0.21%), Russell Investments Group Ltd. (0.18%), Factory Mutual Insurance Co. (0.15%), First Manhattan Co. (0.15%), Swedbank (0.11%) and Canada Pension Plan Investment Board (0.11%). Company insiders that own Allergan plc stock include Brent L Saunders, Maria Teresa Hilado, Nesli Basgoz and Paul Bisaro.

Who sold Allergan plc stock? Who is selling Allergan plc stock?

Allergan plc's stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Russell Investments Group Ltd., Korea Investment CORP, Factory Mutual Insurance Co., Swedbank, Capital Advisors Inc. OK, Chevy Chase Trust Holdings Inc. and Peregrine Capital Management LLC. Company insiders that have sold Allergan plc stock in the last year include Nesli Basgoz and Paul Bisaro.

Who bought Allergan plc stock? Who is buying Allergan plc stock?

Allergan plc's stock was purchased by a variety of institutional investors in the last quarter, including First Manhattan Co., PGGM Investments, Canada Pension Plan Investment Board, Atalanta Sosnoff Capital LLC, Braun Stacey Associates Inc., LaFleur & Godfrey LLC, Verde Servicos Internacionais S.A. and Confluence Investment Management LLC. Company insiders that have bought Allergan plc stock in the last two years include Brent L Saunders, Maria Teresa Hilado and Paul Bisaro.

How do I buy Allergan plc stock?

Shares of Allergan plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Allergan plc stock cost?

One share of Allergan plc stock can currently be purchased for approximately $243.86.

Allergan plc (AGN) Chart for Saturday, April, 29, 2017

This page was last updated on 4/29/2017 by Staff